Genetic Profile of Linezolid-Resistant M. tuberculosis Clinical Strains from Moscow.

ABSTRACT:

Background

Linezolid, bedaquiline, and newer fluoroquinolones are currently placed as priority Group A drugs for the treatment of drug-resistant tuberculosis. The number of reported linezolid-resistant clinical strains is still low, and the correlation of molecular determinants with phenotype is not perfect.

Methods

We determined the linezolid MICs for clinical isolates from the Moscow region and identified mutations in rplC and rrl genes.

Results

All 16 linezolid-resistant isolates had previously reported mutations in the rplC or rrl loci, and 13 of them bore a RplC C154R substitution. Detection of this substitution in a heteroresistant state was not successful, probably, due to the more stable DNA secondary structure of the mutated fragme

SUBMITTER: Ushtanit A 

PROVIDER: S-EPMC8532644 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature